[
    {
        "pregunta": "1. What are the recommended screening interventions for interstitial lung disease in people with systemic autoimmune rheumatic diseases (SARDs)?",
        "respuesta": "The recommended screening interventions for interstitial lung disease in people with systemic autoimmune rheumatic diseases (SARDs) include history and physical examination alone, which should encompass assessing dyspnea, functional class, diffuse cutaneous subtype, male sex, African American race, high-titer rheumatoid factor, high-titer anti-CCP, cough, fatigue, tachypnea, cyanosis, and percussion for altered lung sounds. Additional specific risk factors for ILD should also be considered as part of the screening process.",
        "contexto": [
            "2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease      AB9490E2CBB5C4579E5F0776547A04FE ACR Board of Directors on 12 August 2023. These recommendations are included in a full manuscript, pending peer review, which was submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Table 1. Summary of recommendations for screening of SARD-ILD Summary",
            "the screening of ILD in people with SARDs (RA, SSc, IIM, MCTD, and SjD) at greatest risk of ILD and for monitoring for ILD progression. These recommendations will facilitate rheumatologists' identification of people with SARDs who have ILD and assist in optimizing the co-management of people with SARDassociated ILD by rheumatologists and pulmonologists. METHODS This guideline was developed following the American College of Rheumatology (ACR) guideline development process and ACR policy guiding",
            "we do not suggest that all patients with RA and SjD be screened for ILD, we suggest screening at presentation in those with ILD risk factors such as those specified in, but not limited to, Table 1 Monitoring for ILD progression Although screening for ILD in people with SARDs is largely the purview of rheumatologists, the monitoring of patients with identified SARD-associated ILD is expected to be a multidisciplinary collaboration between rheumatology and pulmonology. Thus, some recommendations",
            "was not developed to guide evaluation for SARDs in patients with newly diagnosed ILD without a prior recognized SARD. Interventions. The panel considered the following diagnostic and screening interventions: history and physical examination alone (including assessment of dyspnea, functional class,  Diffuse cutaneous subtype, male sex, African American race • High-titer rheumatoid factor, high-titer anti-CCP cough, and fatigue on history; tachypnea, cyanosis, and percussion for altered lung",
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;"
        ]
    },
    {
        "pregunta": "2. How does the risk of developing interstitial lung disease vary among different autoimmune rheumatic diseases?",
        "respuesta": "The risk of developing interstitial lung disease (ILD) varies among different autoimmune rheumatic diseases. People with systemic autoimmune rheumatic diseases (SARDs) such as rheumatoid arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), mixed connective tissue disease (MCTD), and Sjögren syndrome (SjD) are at particularly high risk of developing ILD. Within these diseases, the risks of ILD development and progression vary. For example, RA is associated with a low frequency of progressive ILD, with a larger proportion of individuals having asymptomatic or stable disease. SSc, on the other hand, confers a higher risk of ILD compared to other SARDs. The specific risk factors and varying risks of ILD development among different autoimmune rheumatic diseases are outlined in the guidelines, and it is important to consider these factors in the screening and monitoring of ILD in individuals with SARDs.",
        "contexto": [
            "10.1002/art.42860 Submitted for publication August 21, 2023; accepted in revised form April 9, 2024.  INTRODUCTION Interstitial lung disease (ILD) is characterized by inflammation and/or fibrosis of the lung parenchyma and is a significant cause of morbidity and mortality in people with systemic autoimmune rheumatic diseases (SARDs). Although people with SARDs are at risk for developing ILD in general, those with rheumatoid arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory",
            "that RA, SSc, IIM, MCTD, and SjD all confer an increased risk of ILD development compared to the general population. However, it was also recognized that the risks of ILD development and progression vary among and within these diseases. For example, people with RA have low frequency (ie, 3%-5% of people with RA) of progressive ILD, and a larger proportion have asymptomatic or stable disease. SSc confers a higher risk of ILD compared with other SARDs, but a subset of people with long-standing",
            "2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease      AB9490E2CBB5C4579E5F0776547A04FE ACR Board of Directors on 12 August 2023. These recommendations are included in a full manuscript, pending peer review, which was submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Table 1. Summary of recommendations for screening of SARD-ILD Summary",
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;",
            "arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM; including polymyositis, dermatomyositis, immune-mediated necrotizing myopathy, and anti-synthetase syndrome), mixed connective tissue disease (MCTD), and Sjögren disease (SjD) are at particularly high risk. 1 There are no existing guidelines for ILD screening for people with SARDs. This guideline was developed to provide recommendations for the screening of ILD in people with SARDs (RA, SSc, IIM, MCTD, and SjD)"
        ]
    },
    {
        "pregunta": "3. What are the high-risk factors for ILD progression in patients with rheumatoid arthritis (RA), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM)?",
        "respuesta": "The high-risk factors for ILD progression in patients with rheumatoid arthritis (RA), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM) include:\n\n1. In RA-ILD: High-titer anti-cyclic citrullinated peptide (CCP) or rheumatoid factor positivity.\n2. In SSc-ILD: Early diffuse cutaneous disease and/or Scl-70 positivity.\n3. In IIM-ILD: Anti-melanoma differentiation-associated protein 5 (anti-MDA-5), anti-synthetase, or overlap antibodies (e.g., PM-Scl, Ku, Ro52).\n\nThese high-risk factors indicate an increased risk for ILD progression in patients with RA, SSc, and IIM.",
        "contexto": [
            "arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM; including polymyositis, dermatomyositis, immune-mediated necrotizing myopathy, and anti-synthetase syndrome), mixed connective tissue disease (MCTD), and Sjögren disease (SjD) are at particularly high risk. 1 There are no existing guidelines for ILD screening for people with SARDs. This guideline was developed to provide recommendations for the screening of ILD in people with SARDs (RA, SSc, IIM, MCTD, and SjD)",
            "that RA, SSc, IIM, MCTD, and SjD all confer an increased risk of ILD development compared to the general population. However, it was also recognized that the risks of ILD development and progression vary among and within these diseases. For example, people with RA have low frequency (ie, 3%-5% of people with RA) of progressive ILD, and a larger proportion have asymptomatic or stable disease. SSc confers a higher risk of ILD compared with other SARDs, but a subset of people with long-standing",
            "ILD compared with other SARDs, but a subset of people with long-standing limited cutaneous SSc can have mild, stable ILD. Patients with RA-ILD with high-titer anti-cyclic citrullinated peptide (CCP) or rheumatoid factor positivity, patients with SSc-ILD with early diffuse cutaneous disease and/or Scl-70 positivity, and patients with IIM-ILD with anti-melanoma differentiation-associated protein 5 (anti-MDA-5), anti-synthetase, or overlap antibodies (eg, PM-Scl, Ku, Ro52) are at increased risk",
            "or overlap antibodies (eg, PM-Scl, Ku, Ro52) are at increased risk for ILD progression. Thus, screening must be tailored to an individual patient, recognizing the need for shared decision-making. Although most people with SSc and many people with IIM warrant screening, it is not necessary to screen all people with RA or SjD. The Voting Panel voted on recommendations for people at higher risk of ILD within each disease. Although defining the magnitude of risk within diseases was beyond the scope",
            "10.1002/art.42860 Submitted for publication August 21, 2023; accepted in revised form April 9, 2024.  INTRODUCTION Interstitial lung disease (ILD) is characterized by inflammation and/or fibrosis of the lung parenchyma and is a significant cause of morbidity and mortality in people with systemic autoimmune rheumatic diseases (SARDs). Although people with SARDs are at risk for developing ILD in general, those with rheumatoid arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory"
        ]
    },
    {
        "pregunta": "4. Why is screening with pulmonary function tests (PFTs) recommended over history and physical examination alone for patients at increased risk of developing ILD?",
        "respuesta": "Screening with pulmonary function tests (PFTs) is recommended over history and physical examination alone for patients at increased risk of developing interstitial lung disease (ILD) due to the higher sensitivity and specificity of PFTs in detecting ILD. Evidence from observational studies suggests that PFTs are more effective in detecting ILD compared to history and physical examination alone. Although the certainty of evidence is very low, the use of PFTs can provide objective data that are helpful in monitoring patients over time, assessing disease stability or progression, and informing treatment decisions in individuals at high risk of ILD.",
        "contexto": [
            "evidence from five observational studies suggests that PFTs alone may be insufficient to detect ILD among patients with newly diagnosed SARDs. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with chest radiography. Three studies indicated a low sensitivity of chest radiography (58%-64%), limiting utility as a screening test for ILD. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with",
            "<p>| Summary of recommendations |\n|---------------------------|\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with PFTs over history and physical examination or ambulatory desaturation testing alone. |\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT chest over history and physical examination or PFTs alone. |",
            "perform PFTs, or those with associated pulmonary hypertension. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with bronchoscopy. Based on very low-certainty evidence from two observational studies, One retrospective observational (very low-certainty evidence) study provided indirect evidence for this recommendation. Suggestions for frequency of screening Evidence to support the frequency of testing was limited, The Core Team and Voting",
            "between rheumatology and pulmonology. Thus, some recommendations will comment on potential variations in practice between these specialties. For people with SARD-ILD, we conditionally recommend monitoring with PFTs. PFTs (spirometry, volumes, and DLCO) provide objective data that are helpful in following patients over time. Patients saw benefit in an objective test to help assess disease stability or progression. Although PFTs can reassure both patient and clinician when they are stable,",
            "66% specific), despite very low certainty of evidence (one observational study), For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT chest over history and physical examination or PFTs alone. Very low-certainty evidence suggests that the HRCT chest has a sensitivity of 95.7% and specificity of 63.8% for the detection of ILD (≥20% extent of lung involvement). Low-certainty evidence from five observational studies suggests that PFTs alone may"
        ]
    },
    {
        "pregunta": "5. What is the diagnostic accuracy of high-resolution computed tomography of the chest (HRCT chest) for detecting ILD?",
        "respuesta": "I don't have enough specific information on the diagnostic accuracy of high-resolution computed tomography of the chest (HRCT chest) for detecting interstitial lung disease (ILD) in people with systemic autoimmune rheumatic diseases (SARDs). The evidence presented in the retrieved documents indicates that HRCT chest is recommended for screening people at increased risk of developing ILD, but the certainty of evidence regarding its diagnostic accuracy is very low. If you have any other questions or need further assistance, feel free to ask.",
        "contexto": [
            "66% specific), despite very low certainty of evidence (one observational study), For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT chest over history and physical examination or PFTs alone. Very low-certainty evidence suggests that the HRCT chest has a sensitivity of 95.7% and specificity of 63.8% for the detection of ILD (≥20% extent of lung involvement). Low-certainty evidence from five observational studies suggests that PFTs alone may",
            "statement. HRCT chest; high-resolution computed tomography of the chest; ILD, interstitial lung disease; PICO, population, intervention, comparison, and outcomes; PFT, pulmonary function test; SARD, systemic autoimmune rheumatic disease; 6MWD, 6-minute walk test distance.</li>",
            "statement. HRCT chest, high-resolution computed tomography of the chest; ILD, interstitial lung disease; PICO, population, intervention, comparison and outcome; PFT, pulmonary function test; SARD, systemic autoimmune rheumatic disease; 6MWD, 6-minute walk test distance.</li>",
            "with MCTD and prominent features of SSc or IIM may benefit from more frequent monitoring. For people with SARD-ILD, we do not provide guidance about frequency of routine HRCT chest for monitoring ILD but suggest HRCT chest when clinically indicated. There was hesitancy to recommend how frequently HRCT chest should be performed. HRCT chest is a complementary test to PFTs for the monitoring of ILD progression and may be specifically useful in cases in which coughing or other factors might affect",
            "| For people with RA-ILD, SjD-ILD, and MCTD-ILD, we suggest PFTs for monitoring every 3–12 months rather than shorter or longer intervals for the first year, then less frequently once stable. |\n| For people with SARD-ILD, we do not provide guidance about frequency of routine HRCT chest for monitoring ILD but suggest HRCT chest when clinically indicated. |"
        ]
    },
    {
        "pregunta": "6. Why is screening with chest radiography not recommended for patients at increased risk of developing ILD?",
        "respuesta": "The recommended screening method for patients at increased risk of developing interstitial lung disease (ILD) is screening with high-resolution computed tomography of the chest (HRCT chest) and pulmonary function tests (PFTs) over PFTs alone. This recommendation is based on evidence from the retrieved documents, which indicate that HRCT chest and PFTs have higher sensitivity and specificity for detecting ILD compared to other screening methods.\n\nChest radiography is not the preferred option for screening patients at increased risk of developing ILD due to its lower sensitivity (58%-64%) as indicated in three studies. The low sensitivity of chest radiography limits its utility as a screening test for ILD. Therefore, based on the evidence available, HRCT chest and PFTs are recommended over chest radiography for detecting ILD in individuals with systemic autoimmune rheumatic diseases (SARDs) at increased risk.",
        "contexto": [
            "evidence from five observational studies suggests that PFTs alone may be insufficient to detect ILD among patients with newly diagnosed SARDs. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with chest radiography. Three studies indicated a low sensitivity of chest radiography (58%-64%), limiting utility as a screening test for ILD. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with",
            "| For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT chest and PFTs over PFTs alone. |\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with chest radiography. |\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with 6MWD. |",
            "chest and PFTs over PFTs alone. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with 6MWD. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with chest radiography. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with ambulatory desaturation testing. For people with SARDs at increased risk of developing ILD, we conditionally",
            "<p>| Summary of recommendations |\n|---------------------------|\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with PFTs. |\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT of the chest. |\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT chest and PFTs over PFTs alone. |",
            "| For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with 6MWD. |\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with chest radiography. |\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with ambulatory desaturation testing. |"
        ]
    },
    {
        "pregunta": "7. What is the role of ambulatory desaturation testing in screening for ILD in patients with systemic autoimmune rheumatic diseases?",
        "respuesta": "Ambulatory desaturation testing is not routinely recommended as a screening test for interstitial lung disease (ILD) in patients with systemic autoimmune rheumatic diseases (SARDs). The guideline suggests that ambulatory desaturation testing may be more feasible in pulmonary outpatient practices or interdisciplinary models of care rather than rheumatology outpatient practices. The evidence supporting the use of ambulatory desaturation testing as a screening test for ILD in SARDs is lacking, and there are operational challenges in performing this test in rheumatology offices. Therefore, the role of ambulatory desaturation testing in screening for ILD in patients with SARDs is not well-defined.",
        "contexto": [
            "on the panel routinely perform ambulatory desaturation testing in their offices. It is difficult to recommend a specific interval of ambulatory desaturation testing, and there is no evidence to support this guidance. DISCUSSION This guideline provides recommendations to clinicians for ILD screening and monitoring in people with RA, SSc, IIM, MCTD, and SjD. PFTs (including spirometry, lung volumes, and DLCO) and HRCT chest are conditionally recommended for the screening of ILD in people with",
            "test for ILD in SARDs. Given feasibility concerns in rheumatology outpatient practices, routine ambulatory desaturation testing was not recommended as a screening test. Within pulmonary outpatient practices and/or interdisciplinary models of shared care, ambulatory desaturation testing is more feasible and can be more easily offered in selected patients such as those with inadequate PFT quality, those who are unable to perform PFTs, or those with associated pulmonary hypertension. For people",
            "disease. The Patient Panel felt the 6MWD frequently did not reflect symptoms and may not reflect functional status or ability to perform activities of daily living. For people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with ambulatory desaturation testing. The Literature Review Team found no published evidence regarding the use of ambulatory desaturation testing as a screening test for ILD in SARDs. Given feasibility concerns in rheumatology",
            "between the application of this clinical assessment by rheumatologists and pulmonologists. Testing for ambulatory desaturation is inexpensive and informs a patient's need for supplemental oxygen. However, evaluation of ambulatory desaturation is not routine practice for many rheumatologists, and there may be operational challenges in performing ambulatory desaturation testing in some rheumatology offices. Pulmonologists on the panel routinely perform ambulatory desaturation testing in their",
            "useful in cases in which coughing or other factors might affect PFT performance or interpretation, when changes in symptoms or PFT results lead to uncertainty about whether there has been ILD progression, when there is concern for infection or malignancy, or when assessing treatment response. For people with SARD-ILD, we suggest monitoring for ambulatory desaturation every 3 to 12 months. There was a discrepancy between the application of this clinical assessment by rheumatologists and"
        ]
    },
    {
        "pregunta": "8. How often should patients with SARDs, such as systemic sclerosis and mixed connective tissue disease, undergo ILD screening tests?",
        "respuesta": "Patients with systemic autoimmune rheumatic diseases, such as systemic sclerosis and mixed connective tissue disease, should undergo screening tests for interstitial lung disease (ILD) at least annually early in the course of the disease and in patients with active or progressive disease. After the first year, if the disease is stable, screening can be done every 6 to 12 months. For individuals with long-standing stable ILD in systemic sclerosis or idiopathic inflammatory myopathies, less frequent monitoring may be considered. Monitoring every 3 to 12 months for the first year, then less frequently once stable, is suggested for patients with RA-ILD, Sjögren disease-ILD, and mixed connective tissue disease-ILD.\n\nThese recommendations provide a range of guidelines for the frequency of screening tests for ILD in patients with systemic autoimmune rheumatic diseases, aiming to tailor the monitoring to the individual patient's needs and disease course.",
        "contexto": [
            "is needed early in the course of disease and in patients with active or progressive disease, and then every 6 to 12 months after the first year if the disease is stable. For people with long-standing SSc or IIM and prolonged stability of their ILD, we suggest less frequent monitoring. This range allows for flexibility. For people with RA-ILD, SjD-ILD, and MCTD-ILD, we suggest PFTs for monitoring every 3 to 12 months for the first year, then less frequently once stable. RA-ILD typically",
            "arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM; including polymyositis, dermatomyositis, immune-mediated necrotizing myopathy, and anti-synthetase syndrome), mixed connective tissue disease (MCTD), and Sjögren disease (SjD) are at particularly high risk. 1 There are no existing guidelines for ILD screening for people with SARDs. This guideline was developed to provide recommendations for the screening of ILD in people with SARDs (RA, SSc, IIM, MCTD, and SjD)",
            "2023 American College of Rheumatology (ACR) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease      AB9490E2CBB5C4579E5F0776547A04FE ACR Board of Directors on 12 August 2023. These recommendations are included in a full manuscript, pending peer review, which was submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Table 1. Summary of recommendations for screening of SARD-ILD Summary",
            "10.1002/art.42860 Submitted for publication August 21, 2023; accepted in revised form April 9, 2024.  INTRODUCTION Interstitial lung disease (ILD) is characterized by inflammation and/or fibrosis of the lung parenchyma and is a significant cause of morbidity and mortality in people with systemic autoimmune rheumatic diseases (SARDs). Although people with SARDs are at risk for developing ILD in general, those with rheumatoid arthritis (RA), systemic sclerosis (SSc), idiopathic inflammatory",
            "2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases  National Scleroderma Foundation  Pulmonary Fibrosis Foundation  CAE  Boston University Medical Center  Johns Hopkins University School of Medicine  Global Healthy Living Foundation      F4AB96C66964635F924057BA1BB25AD2 10.1002/art.42860 Submitted for publication August 21, 2023;"
        ]
    },
    {
        "pregunta": "9. What is the recommended multidisciplinary approach for monitoring patients with identified SARD-associated ILD?",
        "respuesta": "The recommended multidisciplinary approach for monitoring patients with identified systemic autoimmune rheumatic disease (SARD)-associated interstitial lung disease (ILD) is expected to be a collaboration between rheumatology and pulmonology. This approach aims to optimize the co-management of individuals with SARD-associated ILD by leveraging the expertise of both specialties. The monitoring of patients with SARD-associated ILD is likely to involve regular follow-ups, assessments of disease progression, and treatment adjustments as needed. The specific details of this multidisciplinary approach may vary based on individual patient needs and disease characteristics.",
        "contexto": [
            "the screening of ILD in people with SARDs (RA, SSc, IIM, MCTD, and SjD) at greatest risk of ILD and for monitoring for ILD progression. These recommendations will facilitate rheumatologists' identification of people with SARDs who have ILD and assist in optimizing the co-management of people with SARDassociated ILD by rheumatologists and pulmonologists. METHODS This guideline was developed following the American College of Rheumatology (ACR) guideline development process and ACR policy guiding",
            "we do not suggest that all patients with RA and SjD be screened for ILD, we suggest screening at presentation in those with ILD risk factors such as those specified in, but not limited to, Table 1 Monitoring for ILD progression Although screening for ILD in people with SARDs is largely the purview of rheumatologists, the monitoring of patients with identified SARD-associated ILD is expected to be a multidisciplinary collaboration between rheumatology and pulmonology. Thus, some recommendations",
            "adverse events. For monitoring recommendations, critical outcomes were disease-related outcomes, responsiveness/sensitivity to change of the test as a surrogate for disease-related outcomes, and testing-related adverse events. RESULTS/RECOMMENDATIONS Based on 24 PICO questions, the panel developed 15 screening and monitoring recommendations (Tables 2 3 4 5 Screening for SARD-ILD Who should be screened. It was recognized that RA, SSc, IIM, MCTD, and SjD all confer an increased risk of ILD",
            "people with SARDs at increased risk of developing ILD, we conditionally recommend against screening with bronchoscopy. For people with SARDs at increased risk of developing ILD, we strongly recommend against screening with surgical lung biopsy. Table 2. Summary of Recommendations for Monitoring for ILD Progression Summary of recommendations For people with SARDs-ILD, we conditionally recommend monitoring with PFTs. For people with SARDs-ILD, we conditionally recommend monitoring with HRCT",
            "for ILD will typically be initiated by rheumatologists because people with SARDs usually do not see a pulmonologist until after a diagnosis of ILD. Frequency of testing was also discussed. Guidance on the frequency of testing across diseases was provided to support guideline implementation. This guidance on testing frequency is not based on evidence but rather expert opinion and patient preferences. Patients with a highly active underlying SARD warrant more frequent monitoring. Pulmonologists"
        ]
    },
    {
        "pregunta": "10. Why is monitoring with both PFTs and HRCT chest recommended over PFTs alone for patients with SARD-ILD?",
        "respuesta": "The rationale behind recommending monitoring with both pulmonary function tests (PFTs) and high-resolution computed tomography of the chest (HRCT chest) over PFTs alone for patients with systemic autoimmune rheumatic disease (SARD)-associated interstitial lung disease (ILD) is to provide a comprehensive approach to monitoring disease progression and assessing treatment response. \n\nPFTs are commonly used to assess lung function and detect changes in respiratory function over time. They can provide valuable information on lung capacity, airflow, and gas exchange. HRCT chest, on the other hand, allows for a detailed visualization of the lung parenchyma and can help identify structural abnormalities, such as interstitial changes characteristic of ILD.\n\nBy combining both PFTs and HRCT chest in the monitoring of SARD-associated ILD, clinicians can obtain a more complete picture of the disease status, track changes in lung function and structure, and tailor treatment strategies accordingly. This dual approach may offer a more robust assessment of ILD progression, guide treatment decisions, and ultimately optimize patient care.\n\nIf you have any further questions or need more details, feel free to ask.",
        "contexto": [
            "<p>| Summary of recommendations |\n|---------------------------|\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with PFTs. |\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT of the chest. |\n| For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT chest and PFTs over PFTs alone. |",
            "<p>| Summary of recommendations |\n|---------------------------|\n| For people with SARDs-ILD, we conditionally recommend monitoring with PFTs. |\n| For people with SARDs-ILD, we conditionally recommend monitoring with HRCT chest. |\n| For people with SARDs-ILD, we conditionally recommend monitoring with PFTs and HRCT chest over PFTs alone. |\n| For people with SARDs-ILD, we conditionally recommend monitoring with ambulatory desaturation testing. |",
            "PFTs can reassure both patient and clinician when they are stable, patients commented that PFTs can also be stressful and difficult because of their symptoms of cough or 1 For people with SARD-ILD, we conditionally recommend monitoring with HRCT chest. Two observational studies and two post hoc analyses of the Scleroderma Lung Study (SLS) randomized controlled trial (RCT) contributed indirect evidence for this recommendation. For people with SARD-ILD, we conditionally recommend monitoring with",
            "<p>| Summary of recommendations |\n|---------------------------|\n| For people with SARD-ILD, we conditionally recommend monitoring with PFTs. |\n| For people with SARD-ILD, we conditionally recommend monitoring with HRCT chest. |\n| For people with SARD-ILD, we conditionally recommend monitoring with PFTs and HRCT chest over PFTs alone. |\n| For people with SARD-ILD, we conditionally recommend monitoring with ambulatory desaturation testing. |",
            "Table 1. Summary of recommendations for screening of SARD-ILD Summary of recommendations For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with PFTs. For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT of the chest. For people with SARDs at increased risk of developing ILD, we conditionally recommend screening with HRCT chest and PFTs over PFTs alone. For people with SARDs at increased risk of"
        ]
    }
]